The evidence table tells - point 19 , to chose LMWH over UFH 'initially'.
In the explanation below they tell especially in point 18 and 20, That this data corresponds to selection bias, hence evidence not enough to recommend LMWH over UFH 'during' the procedure or thrombolysis.
Ok that's for anticoagulation before/after endovascular procedure or after thrombolysis and I agree with you [point 18 to 20]. But what about point Number 2 (Page 26) related to C3->D2 for example? They state that LMWH should be used over UFH (COR 1 B-R so quite strong.
That's what they cite but I have to ready It...
Robertson L, Jones LE. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev. 2017 Feb 9;2(2):CD001100. doi: 10.1002/14651858.CD001100.pub4. PMID: 28182249; PMCID: PMC6464611.
"UFH preferred in unstable patients": where did you read this statement in AHA guidelines? I missed
Great Reading.
The evidence table tells - point 19 , to chose LMWH over UFH 'initially'.
In the explanation below they tell especially in point 18 and 20, That this data corresponds to selection bias, hence evidence not enough to recommend LMWH over UFH 'during' the procedure or thrombolysis.
Ok that's for anticoagulation before/after endovascular procedure or after thrombolysis and I agree with you [point 18 to 20]. But what about point Number 2 (Page 26) related to C3->D2 for example? They state that LMWH should be used over UFH (COR 1 B-R so quite strong.
That's what they cite but I have to ready It...
Robertson L, Jones LE. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev. 2017 Feb 9;2(2):CD001100. doi: 10.1002/14651858.CD001100.pub4. PMID: 28182249; PMCID: PMC6464611.
insightful
What about use of tenecteplase and streptokinase in thrombolysis?
Streptokinase is still used.
there are two regimens, normal and accelerated regimen.
About tenecteplase in PE, still evidence is lacking for use.
thanks so much. really helpful. what are your thoughts on using lower dose thrombolytics for managing P.E.
Still proper level of evidence is lacking to consider it an option.